News

PipelineReview.com5h
Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA®
AHMEDABAD, India I August 7, 2025 I Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has solidified ...
PipelineReview.com5h
Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan
Kaken will also provide support for the ALPHA-ORBIT Phase 3 trial in Japan, be responsible for regulatory submissions in Japan, and will reimburse Astria for a portion of the costs of the navenibart ...
PipelineReview.com5h
Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy
DUBLIN, Ireland I August 06, 2025 I Prothena Corporation plc (NASDAQ:PRTA), announced that Novo Nordisk communicated during their second quarter 2025 earnings ...
PipelineReview.com6h
US NCI Sponsors Senhwa Biosciences’ Second Program-IND Submitted for Clinical Trial Targeting MYC-Aberrant Lymphoma
TAIPEI, Taiwan and SAN DIEGO, CA, USA I August 7, 2025 I Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class ...
PipelineReview.com5h
FDA approves expanded indication for AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in cytokine release syndrome (CRS)
INCHEON, South Korea I August 6, 2025 I Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication ...
PipelineReview.com5h
Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta
SAN FRANCISCO, CA, USA I August 06, 2025 I Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in ECLIPSE 3. All ...